top of page

Red & Blue Co., Ltd. Publishes Paper on PAIN BOT’s Pain Diagnosis Performance

작성자 사진: 메디컬포커스메디컬포커스
Introducing a New Paradigm for Pain Diagnosis and Treatment by Complementing Conventional Subjective Methods
Red & Blue Co., Ltd. Publishes Paper on PAIN BOT’s Pain Diagnosis Performance

Red & Blue Co., Ltd., a specialized medical device development company, announced on the 30th that a paper verifying the clinical effectiveness of the diagnostic function of its pain treatment device, PAIN BOT, is set to be published in the international academic journal MDPI Journal Diagnostics.


This study, conducted in collaboration with researchers from the Department of Medical IT Engineering at Soonchunhyang University, objectively analyzed the pain diagnostic performance of PAIN BOT by comparing it with various clinical evaluation indicators.


The paper is titled "Bioelectrical Impedance for Pain Measurements: Clinical Performance Test in Patients with Low Back Pain."


Red & Blue Co., Ltd. Publishes Paper on PAIN BOT’s Pain Diagnosis Performance


PAIN BOT is a Class II combination medical device that integrates low-frequency and ultrasound technologies for musculoskeletal pain treatment and relief. It was utilized in this clinical study for pain diagnosis and evaluation using bioelectrical impedance.


In this study, low-frequency bioelectrical impedance measurements were conducted through PAIN BOT to analyze the electrical properties according to the presence or absence of pain.


Red & Blue Co., Ltd. Publishes Paper on PAIN BOT’s Pain Diagnosis Performance

The research team assessed a total of 85 participants (45 in the normal group and 40 in the patient group) by measuring the bioelectrical impedance of the skin depending on the presence of lower back pain.


The results were then compared with the Oswestry Disability Index (ODI), the Roland-Morris Disability Questionnaire (RMDQ), and the Visual Analogue Scale (VAS).


Through this clinical study, statistically significant differences were observed in resistance, impedance, and phase angle depending on the presence of pain when measured using PAIN BOT's low-frequency bioelectrical impedance technology. The accuracy of predicting the presence of pain was confirmed to be over 95%.


Furthermore, the resistance (R), impedance (Z), and phase angle (PA) indicators used to quantify the severity of pain demonstrated high sensitivity and specificity, proving to be highly reliable for pain diagnosis.


A correlation analysis with VAS confirmed a strong correlation between the severity of pain and the PAIN BOT measurement values, clinically validating the possibility of performing both diagnosis and treatment with a single device.


Yoo Seung-mo, CEO of Red & Blue Co., Ltd., stated, "The results of this study demonstrate the clinical value of PAIN BOT as a non-invasive pain diagnosis and treatment device," adding, "By providing healthcare professionals with highly reliable pain diagnostic data, we expect to contribute to improving patients’ quality of life."


Additionally, PAIN BOT is expected to complement conventional subjective pain diagnosis methods, enable real-time pain monitoring using objective data, and be applicable to both acute and chronic pain patients.


Red & Blue Co., Ltd. plans to continue research and development to expand the clinical applications of PAIN BOT.


This paper is set to be published in the MDPI Journal Diagnostics, which is indexed in the Science Citation Index (SCI) and recognized internationally for its credibility in publishing validated research in the medical and life sciences fields.


The study is expected to introduce a new paradigm in pain diagnosis within the medical community.

댓글 0개

Comentarios


(주)투에이취에프

제호 : 메디컬포커스

발행인 : 유승모

​서울시 강남구 선릉로122길 12, 2층 (삼성동, 부흥빌딩)

전화 : 02-701-9800

등록번호 : 서울 아01261

등록일 : 2010년 6월 3일

편집인 : 김경진

청소년보호책임자 : 유성철

발행일 : 2014년 4월 10일

Copyright ⓒ 2021 메디컬포커스

​(주)투에이취에프의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재 · 복사 · 배포 등을 금합니다.

bottom of page